334 related articles for article (PubMed ID: 33261925)
1. Congenital disorders of glycosylation type IIb with MOGS mutations cause early infantile epileptic encephalopathy, dysmorphic features, and hepatic dysfunction.
Anzai R; Tsuji M; Yamashita S; Wada Y; Okamoto N; Saitsu H; Matsumoto N; Goto T
Brain Dev; 2021 Mar; 43(3):402-410. PubMed ID: 33261925
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of novel mutations in MOGS in a Chinese patient with infantile spams.
Peiwei Zhao ; Peng X; Luo S; Huang Y; Tan L; Shao J; He X
Neurogenetics; 2020 Apr; 21(2):97-104. PubMed ID: 31925597
[TBL] [Abstract][Full Text] [Related]
3. Early onset epileptic and developmental encephalopathy and MOGS variants: a new diagnosis in the whole exome sequencing (WES) ERA : Report of a new patient and review of the literature.
Teutonico F; Volpe C; Proto A; Costi I; Cavallari U; Doneda P; Iascone M; Sturiale L; Barone R; Martinelli S; Vignoli A
Neurogenetics; 2024 Mar; ():. PubMed ID: 38498292
[TBL] [Abstract][Full Text] [Related]
4. Compound heterozygous variants in MOGS inducing congenital disorders of glycosylation (CDG) IIb.
Li M; Xu Y; Wang Y; Yang XA; Jin D
J Hum Genet; 2019 Mar; 64(3):265-268. PubMed ID: 30587846
[TBL] [Abstract][Full Text] [Related]
5. Characteristic dysmorphic features in congenital disorders of glycosylation type IIb.
Kim YM; Seo GH; Jung E; Jang JH; Kim SZ; Lee BH
J Hum Genet; 2018 Mar; 63(3):383-386. PubMed ID: 29235540
[TBL] [Abstract][Full Text] [Related]
6. Exome sequence identified a c.320A > G ALG13 variant in a female with infantile epileptic encephalopathy with normal glycosylation and random X inactivation: Review of the literature.
Hamici S; Bastaki F; Khalifa M
Eur J Med Genet; 2017 Oct; 60(10):541-547. PubMed ID: 28778787
[TBL] [Abstract][Full Text] [Related]
7. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.
Vals MA; Ashikov A; Ilves P; Loorits D; Zeng Q; Barone R; Huijben K; Sykut-Cegielska J; Diogo L; Elias AF; Greenwood RS; Grunewald S; van Hasselt PM; van de Kamp JM; Mancini G; Okninska A; Pajusalu S; Rudd PM; Rustad CF; Salvarinova R; de Vries BBA; Wolf NI; ; Ng BG; Freeze HH; Lefeber DJ; Õunap K
J Inherit Metab Dis; 2019 May; 42(3):553-564. PubMed ID: 30746764
[TBL] [Abstract][Full Text] [Related]
8. Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of Glycosylation.
Kane MS; Davids M; Adams C; Wolfe LA; Cheung HW; Gropman A; Huang Y; ; Ng BG; Freeze HH; Adams DR; Gahl WA; Boerkoel CF
Am J Hum Genet; 2016 Feb; 98(2):339-46. PubMed ID: 26805780
[TBL] [Abstract][Full Text] [Related]
9. MOGS-CDG: Quantitative analysis of the diagnostic Glc
Post MA; de Wit I; Zijlstra FSM; Engelke UFH; van Rooij A; Christodoulou J; Tan TY; Le Fevre A; Jin D; Yaplito-Lee J; Lee BH; Low KJ; Mallick AA; Õunap K; Pitt J; Reardon W; Vals MA; Wortmann SB; Wessels HJCT; Bärenfänger M; van Karnebeek CDM; Lefeber DJ
J Inherit Metab Dis; 2023 Mar; 46(2):313-325. PubMed ID: 36651519
[TBL] [Abstract][Full Text] [Related]
10. Glycosylation, hypogammaglobulinemia, and resistance to viral infections.
Sadat MA; Moir S; Chun TW; Lusso P; Kaplan G; Wolfe L; Memoli MJ; He M; Vega H; Kim LJY; Huang Y; Hussein N; Nievas E; Mitchell R; Garofalo M; Louie A; Ireland DC; Grunes C; Cimbro R; Patel V; Holzapfel G; Salahuddin D; Bristol T; Adams D; Marciano BE; Hegde M; Li Y; Calvo KR; Stoddard J; Justement JS; Jacques J; Priel DAL; Murray D; Sun P; Kuhns DB; Boerkoel CF; Chiorini JA; Di Pasquale G; Verthelyi D; Rosenzweig SD
N Engl J Med; 2014 Apr; 370(17):1615-1625. PubMed ID: 24716661
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of glucosidase I-mediated glycoprotein deglucosylation results in a sick phenotype in fission yeasts: Model for the human MOGS-CDG disorder.
Gallo GL; Valko A; Aramburu SI; Etchegaray E; Völker C; Parodi AJ; D'Alessio C
J Biol Chem; 2018 Dec; 293(52):19957-19973. PubMed ID: 30389790
[TBL] [Abstract][Full Text] [Related]
12. DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy.
Barone R; Aiello C; Race V; Morava E; Foulquier F; Riemersma M; Passarelli C; Concolino D; Carella M; Santorelli F; Vleugels W; Mercuri E; Garozzo D; Sturiale L; Messina S; Jaeken J; Fiumara A; Wevers RA; Bertini E; Matthijs G; Lefeber DJ
Ann Neurol; 2012 Oct; 72(4):550-8. PubMed ID: 23109149
[TBL] [Abstract][Full Text] [Related]
13. Dolichol kinase deficiency (DOLK-CDG) with a purely neurological presentation caused by a novel mutation.
Helander A; Stödberg T; Jaeken J; Matthijs G; Eriksson M; Eggertsen G
Mol Genet Metab; 2013 Nov; 110(3):342-4. PubMed ID: 23890587
[TBL] [Abstract][Full Text] [Related]
14. Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: Clinical description, biomarker status, biochemical analysis, and treatment suggestions.
Ng BG; Eklund EA; Shiryaev SA; Dong YY; Abbott MA; Asteggiano C; Bamshad MJ; Barr E; Bernstein JA; Chelakkadan S; Christodoulou J; Chung WK; Ciliberto MA; Cousin J; Gardiner F; Ghosh S; Graf WD; Grunewald S; Hammond K; Hauser NS; Hoganson GE; Houck KM; Kohler JN; Morava E; Larson AA; Liu P; Madathil S; McCormack C; Meeks NJL; Miller R; Monaghan KG; Nickerson DA; Palculict TB; Papazoglu GM; Pletcher BA; Scheffer IE; Schenone AB; Schnur RE; Si Y; Rowe LJ; Serrano Russi AH; Russo RS; Thabet F; Tuite A; Villanueva MM; Wang RY; Webster RI; Wilson D; Zalan A; ; Wolfe LA; Rosenfeld JA; Rhodes L; Freeze HH
J Inherit Metab Dis; 2020 Nov; 43(6):1333-1348. PubMed ID: 32681751
[TBL] [Abstract][Full Text] [Related]
15. Serum N-glycomics of a novel CDG-IIb patient reveals aberrant IgG glycosylation.
Beimdiek J; Hennig R; Burock R; Puk O; Biskup S; Rapp E; Lesinski-Schiedat A; Buettner FFR; Das AM
Glycobiology; 2022 Apr; 32(5):380-390. PubMed ID: 35137040
[TBL] [Abstract][Full Text] [Related]
16. Epileptic spasms in congenital disorders of glycosylation.
Pereira AG; Bahi-Buisson N; Barnerias C; Boddaert N; Nabbout R; de Lonlay P; Kaminska A; Eisermann M
Epileptic Disord; 2017 Mar; 19(1):15-23. PubMed ID: 28300031
[TBL] [Abstract][Full Text] [Related]
17. Epilepsy and movement disorders in CDG: Report on the oldest-known MOGS-CDG patient.
Lo Barco T; Osanni E; Bordugo A; Rodella G; Iascone M; Tenconi R; Barone R; Dalla Bernardina B; Cantalupo G
Am J Med Genet A; 2021 Jan; 185(1):219-222. PubMed ID: 33058492
[TBL] [Abstract][Full Text] [Related]
18. ALG13-CDG with Infantile Spasms in a Male Patient Due to a De Novo ALG13 Gene Mutation.
Galama WH; Verhaagen-van den Akker SLJ; Lefeber DJ; Feenstra I; Verrips A
JIMD Rep; 2018; 40():11-16. PubMed ID: 28887793
[TBL] [Abstract][Full Text] [Related]
19. Congenital defects of glycosylation: Novel presentations with mainly neurological involvement and variable dysmorphic features.
İnci A; Cengiz B; Biberoğlu G; Okur İ; Arhan E; Öner AY; Kasapkara ÇS; Küçükçongar A; Tümer L; Ezgu F
Am J Med Genet A; 2021 Sep; 185(9):2739-2747. PubMed ID: 33960646
[TBL] [Abstract][Full Text] [Related]
20. A case of ALG11-congenital disorders of glycosylation diagnosed by post-mortem whole exome sequencing.
Arai Y; Okanishi T; Kanai S; Okazaki T; Koshimizu E; Miyatake S; Maeoka Y; Fujimoto A; Matsumoto N; Maegaki Y
Brain Dev; 2022 Nov; 44(10):732-736. PubMed ID: 35907674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
